
<script type="text/javascript">
<!--
document.write('<div id="oa_widget"></div>');
document.write('<script type="text/javascript" src="https://www.openaire.eu/index.php?option=com_openaire&view=widget&format=raw&projectId=undefined&type=result"></script>');
-->
</script>doi: 10.3322/caac.21185
pmid: 23818335
AbstractAnswer questions and earn CME/CNEEsophageal adenocarcinoma (EAC) is characterized by 6 striking features: increasing incidence, male predominance, lack of preventive measures, opportunities for early detection, demanding surgical therapy and care, and poor prognosis. Reasons for its rapidly increasing incidence include the rising prevalence of gastroesophageal reflux and obesity, combined with the decreasing prevalence of Helicobacter pylori infection. The strong male predominance remains unexplained, but hormonal influence might play an important role. Future prevention might include the treatment of reflux or obesity or chemoprevention with nonsteroidal antiinflammatory drugs or statins, but no evidence‐based preventive measures are currently available. Likely future developments include endoscopic screening of better defined high‐risk groups for EAC. Individuals with Barrett esophagus might benefit from surveillance, at least those with dysplasia, but screening and surveillance strategies need careful evaluation to be feasible and cost‐effective. The surgery for EAC is more extensive than virtually any other standard procedure, and postoperative survival, health‐related quality of life, and nutrition need to be improved (eg, by improved treatment, better decision‐making, and more individually tailored follow‐up). Promising clinical developments include increased survival after preoperative chemoradiotherapy, the potentially reduced impact on health‐related quality of life after minimally invasive surgery, and the new endoscopic therapies for dysplastic Barrett esophagus or early EAC. The overall survival rates are improving slightly, but poor prognosis remains a challenge. CA Cancer J Clin 2013;63:232–248. ©2013 American Cancer Society.
MINIMALLY INVASIVE ESOPHAGECTOMY, Esophageal Neoplasms, CLINICAL DECISION-MAKING, 610, Adenocarcinoma, Endoscopy, Gastrointestinal, Helicobacter Infections, INTERNATIONAL BEACON CONSORTIUM, Barrett Esophagus, QUALITY-OF-LIFE, Biomarkers, Tumor, Humans, patterns, Genetic Predisposition to Disease, Gonadal Steroid Hormones, Early Detection of Cancer, esophagus, therapy, Barrett esophagus, Helicobacter pylori, Anti-Inflammatory Agents, Non-Steroidal, GASTROESOPHAGEAL-REFLUX SYMPTOMS, NONSTEROIDAL ANTIINFLAMMATORY DRUGS, RANDOMIZED CONTROLLED-TRIAL, Genes, erbB-2, Combined Modality Therapy, HELICOBACTER-PYLORI INFECTION, health-related quality of life, BODY-MASS INDEX, Esophagectomy, Breast Feeding, incidence, Critical Pathways, Gastroesophageal Reflux, prognosis, CARDIA CANCER-SURGERY, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Deglutition Disorders, neoplasm
MINIMALLY INVASIVE ESOPHAGECTOMY, Esophageal Neoplasms, CLINICAL DECISION-MAKING, 610, Adenocarcinoma, Endoscopy, Gastrointestinal, Helicobacter Infections, INTERNATIONAL BEACON CONSORTIUM, Barrett Esophagus, QUALITY-OF-LIFE, Biomarkers, Tumor, Humans, patterns, Genetic Predisposition to Disease, Gonadal Steroid Hormones, Early Detection of Cancer, esophagus, therapy, Barrett esophagus, Helicobacter pylori, Anti-Inflammatory Agents, Non-Steroidal, GASTROESOPHAGEAL-REFLUX SYMPTOMS, NONSTEROIDAL ANTIINFLAMMATORY DRUGS, RANDOMIZED CONTROLLED-TRIAL, Genes, erbB-2, Combined Modality Therapy, HELICOBACTER-PYLORI INFECTION, health-related quality of life, BODY-MASS INDEX, Esophagectomy, Breast Feeding, incidence, Critical Pathways, Gastroesophageal Reflux, prognosis, CARDIA CANCER-SURGERY, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Deglutition Disorders, neoplasm
| citations This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | 280 | |
| popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network. | Top 1% | |
| influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | Top 1% | |
| impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network. | Top 1% |
